Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

 
      
    

View in Other Languages

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/29/2020 10:35:36 AM 3194

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities for the period ending 31 March 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) to be granted new key Progenza patent in U.S.

🕔3/23/2020 9:42:44 AM 3143

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the U.S Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for the Company's lead stem cell platform technology, Progenza, in the U.S.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives A$1.6M Milestone Payment from Kyocera

🕔3/20/2020 9:49:10 AM 3451

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, Today received a non-refundable milestone payment of 100,000,000 JPY (approx. A$1.6M) from Kyocera Corporation (TYO:6971) as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read Full Article

Regeneus Ltd (ASX:RGS) Signs MOU with Kyocera Corporation

🕔3/2/2020 10:23:45 AM 4617

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has signed a non-binding MOU with Kyocera Corporation (Kyocera, TYO:6971).

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Results & Business Update

🕔2/28/2020 4:16:21 PM 3443

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today released its Half-Year Financial Results and Appendix 4D for the period ended 31 December 2019 (H1 FY20).

Read Full Article

Regeneus Ltd (ASX:RGS) Directors Provide $4m Loan Facility

🕔2/28/2020 4:09:21 PM 2954

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced its Board of Directors has put in place loan facilities totalling $4 million to extend the Company's funding runway to support negotiations to license and commercialise Progenza for knee osteoarthritis (Progenza OA) in Japan.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly

🕔1/31/2020 9:48:10 AM 4484

Regeneus Ltd (ASX:RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, releases its quarterly cashflow report and review of operational activities for the period ending 31 December 2019 (Q2 FY20).

Read Full Article

Regeneus Ltd (ASX:RGS) AGC Agreement Termination Paves Way for Commercial Partner

🕔12/20/2019 10:33:02 AM 5319

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has come to a mutual agreement with Japan-based manufacturer AGC Inc to terminate their exclusive manufacturing licence and joint venture agreement.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives Innovation Grant

🕔12/18/2019 10:48:37 AM 4438

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has received $50K in funding as part of the Innovation Connections Grant from the Australian Government's Department of Industry, Innovation and Science.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO AGM Presentation

🕔11/21/2019 3:15:30 PM 3456

2019 was a productive year as we continued our aim of commercialising Progenza and Sygenus, our core regenerative medicine technology platforms. In particular, our focus has been on the lead platform, Progenza, which has shown positive results for treating osteoarthritis in its Phase 1 trials.

Read Full Article
###

217,424 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 326) (Last 30 Days: 1191) (Since Published: 100274) 

Company Data

    Headquarters
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

More News Results

  • 2024/03/28: Regeneus secures shareholder approval for merger*
  • 2024/03/28: Results of Meeting*
  • 2024/03/20: Optimisation of Progenza Patent Portfolio*
  • 2024/02/29: Half Yearly Report and Accounts*
  • 2024/02/23: Letter to Shareholders - GM*
  • 2024/02/23: Notice of General Meeting/Proxy Form*
*refer to company website

Presentations

Download Presentation

Research Report

Download Presentation

Quarterly Report

Download Presentation

Social Media